title: Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer.
abstract: OBJECTIVE
  Advanced ovarian cancer typically spreads in a diffuse intra-abdominal fashion. This characteristic suggests that combined radical surgery and intraperitoneal chemotherapy may be a useful treatment procedure. The purpose of this study was to review patients submitted to surgical debulking and hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) and to evaluate the potential prognostic survival factors for advanced epithelial ovarian cancer in our center.
  
  
  METHODS
  A series of patients (N = 33) diagnosed of peritoneal carcinomatosis for epithelial ovarian cancer (stage III) from January 1997 to December 2004 submitted to radical surgery-peritonectomy and HIIC with paclitaxel was included in this study; 19 primary ovarian cancer and 14 recurrent ovarian cancer.
  
  
  RESULTS
  Cytoreduction R0 (P = 0.018) and negative lymph nodes (P = 0.005) were covariables for major prognostic survival. Patients with optimal cytoreduction R0 obtained survival rates of 63% at 5 years in recurrent ovarian cancer and 60% in primary ovarian cancer, 71% and 63%, respectively with associated subtotal infra-abdominal peritonectomy, and even better results if negative lymph nodes.
  
  
  CONCLUSIONS
  Radical surgery-peritonectomy with HIIQ has been shown to be a surgical procedure with high tolerability, low morbimortality, enhanced survival, and prolonged disease-free interval in patients with peritoneal carcinomatosis so much for recurrent or primary ovarian cancer.
authors.affiliation: Department of General Surgery, Reina Sofia University Hospital, Córdoba, Spain.
authors.forename: Sebastián
authors.initials: S
authors.lastname: Rufián
authors.forename: Francisco C
authors.initials: FC
authors.lastname: Muñoz-Casares
authors.forename: Javier
authors.initials: J
authors.lastname: Briceño
authors.forename: Carlos J
authors.initials: CJ
authors.lastname: Díaz
authors.forename: María J
authors.initials: MJ
authors.lastname: Rubio
authors.forename: Rosa
authors.initials: R
authors.lastname: Ortega
authors.forename: Rubén
authors.initials: R
authors.lastname: Ciria
authors.forename: Manuel
authors.initials: M
authors.lastname: Morillo
authors.forename: Enrique
authors.initials: E
authors.lastname: Aranda
authors.forename: Jordi
authors.initials: J
authors.lastname: Muntané
authors.forename: Carlos
authors.initials: C
authors.lastname: Pera
mesh_terms: D000328:Adult; D000368:Aged; D010478:Chemotherapy, Cancer, Regional Perfusion; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007430:Intraoperative Care; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000601:surgery*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D010537:Peritoneum / Q000601:surgery*; D011379:Prognosis; D015996:Survival Rate